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Abstract 
Glioblastoma (GBM) is a type of intracranial brain tumor, for which there is no cure. In spite of 
advances in surgery, chemotherapy and radiotherapy, patients die within a year of diagnosis. 
Therefore, there is a critical need to develop novel therapeutic approaches for this disease. Gene 
therapy, which is the use of genes or other nucleic acids as drugs, is a powerful new treatment strategy 
which can be developed to treat GBM. Several treatment modalities are amenable for gene therapy 
implementation, e.g. conditional cytotoxic approaches, targeted delivery of toxins into the tumor 
mass, immune stimulatory strategies, and these will all be the focus of this review. 
Both conditional cytotoxicity and targeted toxin mediated tumor death, are aimed at eliminating an 
established tumor mass and preventing further growth. Tumors employ several defensive strategies 
that suppress and inhibit anti-tumor immune responses. A better understanding of the mechanisms 
involved in eliciting anti-tumor immune responses has identified promising targets for 
immunotherapy. Immunotherapy is designed to aid the immune system to recognize and destroy 
tumor cells in order to eliminate the tumor burden. Also, immune-therapeutic strategies have the 
added advantage that an activated immune system has the capability of recognizing tumor cells at 
distant sites from the primary tumor, therefore targeting metastasis distant from the primary tumor 
locale. Pre-clinical models and clinical trials have demonstrated that in spite of their location within 
the central nervous system (CNS), a tissue described as „immune privileged‟, brain tumors can be 
effectively targeted by the activated immune system following various immunotherapeutic strategies. 
This review will highlight recent advances in brain tumor immunotherapy, with particular emphasis 
on advances made using gene therapy strategies, as well as reviewing other novel therapies that can 
be used in combination with immunotherapy. Another important aspect of implementing gene 
therapy in the clinical arena is to be able to image the targeting of the therapeutics to the tumors, 
treatment effectiveness and progression of disease. We have therefore reviewed the most exciting 
non-invasive, in vivo imaging techniques which can be used in combination with gene therapy to 
monitor therapeutic efficacy over time. 
INTRODUCTION 
Brain cancers account for 1.4% of all cancers [1]. The most common primary brain tumor is 
the glioblastoma multiforme (GBM), that accounts for 40% of all brain tumors. While overall 
accounting for a small percentage of total cancer cases, GBM is highly aggressive with the 
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average patient surviving no more than 12-18 months [2,3]. GBM are highly proliferative, 
diffusely invasive, immunosuppressive, and highly vascularized tumors [4]. Current treatment 
of GBM involves surgery, chemo- and radiotherapy; however, these therapies are only 
marginally effective in altering the ultimate progression of this disease. After resection of the 
tumor mass, survival depends on whether chemo- and radiation therapies are able to eliminate 
the infiltrating cells [5] which invade healthy tissue. Genomic analysis of patients with GBM 
has led to the identified a subpopulation of GBM that has previously been unidentified. These 
patients respond well to current therapies and have a median survival time of more than 6 years 
[6]. However, the majority of patients with GBM respond very poorly to current treatments 
and the mean survival time following tumor resection is less than 18 months. Consequently, 
new effective therapies are urgently needed to improve survival and the quality of life in 
patients diagnosed with GBM. 
Gene therapy, which is the use of nucleic acids as medicines, provides a novel alternative 
therapeutic approach which can be harnessed to develop more effective treatments for GBM. 
The most attractive therapeutic targets to develop gene therapies for GBM are conditional 
cytotoxic genes, targeted cytotoxins which selectively bind to and kill tumor cells, anti- 
angiogenic molecules which inhibit the formation of new blood vessels, pro-apoptotic genes, 
molecules that block signal trasduction pathways know to be activated in GBM, genes that 
express proteins that block growth factor receptors present in tumor cells, and also oncolytic 
viruses which will specifically replicate within cancer cells, leading to their death. Gene 
delivery vectors can also be used to deliver molecules which will enhance the immune system 
of the host with the aim of producing an effective systemic anti-tumor immune response. In 
this review, we will discuss the immune system within the CNS and how we can harness the 
power of gene therapy to mount an effective immune response against GBM. We will also 
discuss targeted therapeutic approaches which aim to deliver toxins selectively into tumor cells. 
In view of the importance of being able to monitor disease progression and persistence of gene 
therapies in vivo over time, we will also review current non-invasive imaging approaches which 
can be used in conjunction with gene therapy. 
IMMUNE BASED GENE THERAPIES FOR GBM 
Immunotherapy has become an exciting area of research for treating tumors where 
conventional treatment modalities have remained ineffective. The basic premise of a role of 
the immune system in rejection of tumors, specifically allografts, was demonstrated more than 
50 years ago [7,8]. This was an early example of how immune tolerance can lead to tumor 
growth. Tumors generally express different levels of proteins than normal surrounding tissue, 
and some of these proteins contain amino acid substitutions or deletions, or changes in 
phosphorylation or glycosylation. Any of these changes in proteins expressed by tumors can 
be sufficient for the immune system to recognize specifically proteins expressed by tumors as 
antigenic, and mount an immune response against these proteins. There is some anecdotal 
evidence in the literature of spontaneous regression of skin tumors, or even brain tumors 
following infection, and it is believed that the immune system can mediate tumor rejection in 
these cases [9-11]. However, this is not a common event and tumors secrete many anti- 
inflammatory mediators and other proteins that can stifle the development of an effective anti- 
tumor response. It has also emerged recently that regulatory T cells are commonly elevated in 
patients with tumors and they play an active role in suppressing the response of the immune 
system to the tumors [12]. With recent advances in our understanding of the components of 
the immune system that are involved in invoking or repressing immune responses it has become 
feasible to develop novel therapies that specifically target and eliminate tumors. A promising 
field of research may be to stimulate the immune system against the tumor by modulating the 
expression of cytokines using gene therapy. While immunotherapy is a promising approach to 
brain tumor treatment, both the anatomical structure and immune milieu of the brain in 
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conjunction with the immunological features of brain tumors create a scenario in which 
effective immunotherapy faces many challenges. Below we will discuss some of the challenges 
that need to be surmounted before any of these therapies find their way to treat human GBM 
patients. 
THE BRAIN IMMUNE SYSTEM 
For the immune system to work effectively, it must be able to constantly monitor for the 
presence of foreign agents. This is known as the afferent arm of the immune system. 
Additionally, once a foreign agent is detected, a link between the innate and adaptive immune 
system must be made to activate the maturation and proliferation of cellular components of the 
adaptive immune response. This process is commonly referred to as the efferent arm of the 
immune system. In peripheral tissues and organs, innate immune cells such as macrophages 
and neutrophils constantly circulate and monitor for antigen expression and pathogen invasion. 
Macrophages and neutrophils phagocytose cell debris and other small particles, and 
macrophages display this processed antigen to T-cells. Neutrophils usually die shortly after 
phagocytosis and have not been considered very important as antigen presenting cells; 
however, recently it has been shown that cytokines produced at the site of inflammation can 
suppress apoptosis in neutrophils, and under these conditions neutrophils can become effective 
antigen presenting cells [13]. When appropriately stimulated, T-cells release cytokines and 
chemokines to induce activation of the adaptive immune response. Essential to activation of 
adaptive immunity is the presentation of antigen to T-cells by professional antigen presenting 
cells (APCs), the most efficient of whom are dendritic cells. Dendritic cells (DCs) migrate to 
the draining lymph nodes to present antigens to T-cells. Clonal expansion and activation 
CD4+ T-cells, CD8+ T-cells and B-cells that recognize this antigen then results in the 
eradication of the antigen by the immune system. This process can also lead to the induction 
of memory to prevent future infection from developing. A key requirement for DC activation 
and the initiation of both innate and adaptive immune resposnes is the stimulation of Toll-like 
receptors (TLR). TLRs are expressed on DCs and bind with conserved pathogen associated 
molecular patterns (PAMP) and increase the expression of co-stimulatory molecules on the 
surface of DCs and other APCs [14]. In the absence of co-stimulatory molecules, presentation 
of antigen to T-cells usually leads to T-cell tolerance. 
The brain is an organ with specialized mechanisms to protect and maintain its functions. Among 
the specialized mechanisms is the interaction between the immune system and the brain 
parenchyma, which has an immune system that works in different ways when compared to 
peripheral sites, outside the central nervous system. For instance, if a pathogen is injected 
directly into the brain parenchyma, without reaching the brain ventricular system, a transient 
innate immune response occurs [15-24]; however, no adaptive immune response is mounted 
excusively from within the CNS. Immune responses in the brain are limited by several factors. 
Although immune cells are found within the cerebrospinal fluid (CSF), which drains into the 
central lymphatic system of the body [25], lymphatic surveillance, observed in the rest of the 
body, is not very efficient within the brain parenchyma. Foreign proteins and other antigens 
that exit the central nervous system (CNS) through the ventricular system can be phagocytosed 
and transported to peripheral lymphoid organs where they can elicit an adaptive immune 
response. Likewise, activated memory T-cells can detect antigen within the CNS, and target 
cells displaying antigenic epitopes. However, in the brain parenchyma of higher vertebrates 
there is a complete absence of lymphatic structures, and a noticeable absence of immune cells. 
Neutrophils, the largest population of circulating leukocytes involved in innate immunity, are 
rarely detected in either the CSF or brain parenchyma [25,26]. DCs have not been detected in 
the normal brain [25,27,28] although they are observed in the meninges and choroid plexi 
[17,20,29-32]. Under inflammatory conditions both immature and mature DCs can infiltrate 
into the brain [28,32-38]. While T-cells make up 80% of CSF cells [39], their presence within 
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the brain parenchyma is limited unless an inflammatory condition exists. If a peripheral 
immune response is elicited against an antigen which is present within the brain parenchyma, 
then the activated immune cells can migrate into the CNS, and recognize the foreign antigen. 
This suggests that the afferent arm of adaptive immunity is deficient in the CNS and this in 
turn limits the response of the immune system to antigens which are exclusively located within 
the CNS. 
CHALLENGES IN BRAIN TUMOR IMMUNOTHERAPY 
Immunotherapy within the central nervous system has unique challenges based on the 
anatomical characteristics of the brain; however, the presence of a GBM adds another set of 
challenges (Fig. 1). GBM create an environment that is favorable to their continued growth, 
including evading detection by the immune system by creating an immunosuppressive 
environment, in part through the secretion of the powerful immunesuppressant TGF-β [40]. 
Glioma patients have been characterized as anergic to common bacterial antigens, unable to 
mount delayed type hypersensitivity responses, decreased circulating T-cells, depressed in 
vitro proliferation responses of T-cells to mitogens, decreased antibody response, and 
decreased antibody and T-cell cytotoxicity [41-47]. Interestingly, these peripheral dysfunctions 
can be partially reversed upon tumor resection, clearly implicating tumor involvement in global 
immunosuppression [48]. 
While the glioma itself is infiltrated mainly with CD8+ T-cells [49-53], the number of 
peripheral T-cells in glioma patients are reduced [46]. Particularly affected are the number of 
CD4+ T-cells whose reduction disrupts the ratio of CD4+:CD8+ T-cells [54-56]. The T-cells 
isolated peripherally from glioma patients do not respond to mitogen in proliferation assays 
[57-59] nor do they serve as helper T-cells (TH) in vitro [56]. T-cells from glioma patients 
make and secrete less of the cytokine IL-2 essential for proper T-cell proliferation, and again, 
CD4+ TH cells are more profoundly affected [60,61]. Human GBM are highly infiltrated with 
macrophages, which comprise up to 30% of the tumor mass [49]. Glioma patients‟ monocytes 
have decreased MHC II expression on their cell surfaces as well as decreased IL-1β secretion 
[62], which limits their ability to properly present antigens to T-cells. In addition to 
immunosuppressive effects peripherally, tumor infiltrating monocytes may enhance glioma 
growth through the production of growth factors [49,52,63,64], promotion of angiogenesis 
[65-67] and tumor invasion [68]. Together, this evidence indicates that the environment created 
by glioma cells actively affects the ability of the cellular and humoral adaptive immune 
response to function within the tumor or become activated in the periphery, limiting the ability 
of the immune system to eliminate the tumor (Fig. 1). 
IMMUNOSUPPRESSION BY BRAIN TUMORS 
Effects on peripheral immune cells may be mediated by the immunosuppressive factors 
secreted intracranially by glioma cells [5,40]. Originally called glioblastoma cell-derived T- 
cell suppressor factor [69], transforming growth factor-β (TGF-β) is the most well 
characterized of these factors [41,63,69-78]. TGF-β is not produced in the normal brain but is 
overexpressed by gliomas [73,74] and can act either to enhance or suppress tumor growth 
depending on the stage of tumor development [4]. TGF-β directly inhibits B cell and T-cell 
proliferation, cytotoxic T-cell development, monocyte cytokine marker expression, cytokine 
secretion, and also promotes migration of tumor cells [40,63,69,73,75,76,79-85]. Within the 
glioma mass, TGF-β downregulates MHC class II expression, decreasing antigen presentation 
to CD4+ T-cells [86]. TGF-β suppresses the cytotoxic response triggered by tumor infiltrating 
T-cells, and has been linked to the promotion of angiogenesis [87], tumor stroma formation 
[73,88] and decreasing the number infiltration of T-cells, Natural Killer (NK) cells and 
macrophages [89]. While many studies show links between TGF-β secretion and 
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immunosuppression, others indicate that TGF-β alone is not sufficient to account for the 
immunosuppression observed in GBM patients [40,90,91]. 
Other potential cytokines involved in GBM-induced immunosuppression are IL-10 [90] and 
Prostaglandin E2 (PGE) [92,93]. IL-10 was identified as a cytokine synthesis inhibitory factor 
affecting the production of a wide range of cytokines. The role of IL-10 is controversial and 
can both enhance and inhibit glioma progression. Although IL-10 secretion from glioma cells 
inhibits IFNγ and TNFα production, both of which are required for anti-tumor T-cell 
proliferation and maturation [90,94]. Conversely, the use of IL-10 as a therapeutic agent 
enhanced anti tumor immune responses [95]. While IL-10‟s role in glioma mediated 
immunosuppression is controversial, PGE directly decreases lymphokine activated killer cell 
activity, T-cell activation and proliferation, and causes down regulation of MHC class II 
molecules [96]. PGE may be important in the T-cell suppression observed in glioma, although 
in vitro levels of PGE required for such effects are not physiologically relevant thereby 
indicating it alone is not sufficient for glioma mediated immunosuppression [97]. 
Immunotherapy would overcome the difficulties currently encountered in brain cancer 
treatment. Researchers have been actively exploring the potential of gene therapy to deliver 
immune-target molecules to improve survival in pre-clinical models of glioma and also in 
clinical trials. Interleukins, interferons, co-stimulatory molecules, death ligands, transduced 
dendritic cells and immune cell growth factors have all been evaluated for anti-tumor effects 
and will be discussed in the following sections. 
GENE THERAPY OF BRAIN TUMORS USING DEATH RECEPTOR LIGANDS 
The TNF receptor superfamily is a large group of receptors that play important roles in cell 
survival, proliferation, differentiation and apoptosis. Many of these receptors appear to have 
evolved in parallel with novel components of the vertebrate immune system and are important 
mediators of many immune responses [98]. A subfamily of the TNF receptor superfamily are 
death receptors, characterized by the presence of a conserved intracellular motif called the 
death domain that can activate the apoptotic machinery of the cell. They regulate tissue 
homeostasis by inducing cell death after binding with the corresponding death ligand [99]. 
Glioma and other brain tumors have been shown to express death receptors such as the Fas 
receptor or TRAIL receptors (TRAILR1 and TRAILR2) [100,101]. Expression of the 
corresponding death ligands, Fas ligand and TRAIL, in glioma using gene therapy has been 
studied for their efficacy to induce apoptosis in the tumor cells. Many of these studies have 
focused on the cytotoxicity in vitro, when glioma cell lines are infected with viral vectors 
expressing either Fas ligand or TRAIL [102-106]. Despite some promising results in pre- 
clinical models of glioma [107-109], Fas ligand and TRAIL have yet to demonstrate efficacy 
in treating human patients with brain tumors. 
GENE THERAPY OF BRAIN TUMORS USING INTERFERONS 
Interferons are secreted by cells in response to viral infections or other inflammatory signals 
and trigger potent anti-viral and anti-proliferative effects, including increasing the expression 
of death receptors and other components of the apoptotic program, arresting the cell cycle and 
stimulating the maturation of several effector immune cells [110,111]. Two families of 
interferons have been described, based on their ability to bind with Interferon receptor I or 
Interferon receptor II; type I interferons include Interferon α (IFNα), Interferon β (IFNβ) and 
Interferon ω (IFNω), while the only type II interferon described to date is Interferon γ (IFNγ) 
[111]. Type I and type II interferon receptors are present on most somatic cell in the body, and 
are also expressed on many tumors. In part due to their potent anti-proliferative function and 
their ability to stimulate the immune system, interferons have been evaluated as therapeutic 
agents in a number of pre-clinical trials in brain tumors. 
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Type I Interferons 
Type I interferons (IFNα, IFNβ, IFNω) are expressed by most somatic cells immediately 
following infection with a virus. They are also produced, in much greater quantities, by 
Interferon Producing Cells (IPCs) of the immune system. These cells have since been identified 
as plasmacytoid dendritic cells, a distinct lineage of dendritic cell found distributed throughout 
the body [112,113]. Type I interferons possesses several tumorstatic or tumorcidal effects 
including cell cycle inhibition [114,115] and induction of apoptosis [116,117]. In addition, a 
cluster of type I interferon genes are commonly deleted from the genome of human gliomas 
[118,119] indicating that this pathway may play a role in glioma progression. Consequently, 
several groups have assessed the potential of type I interferon gene delivery to improve survival 
in pre-clinical glioma models. In one study, it was found that direct intratumoral injection of 
replication deficient adenovirus expressing IFNα significantly improved survival in a mouse 
model of glioma. The authors found that survival was greatly enhanced when DCs were injected 
into the tumor mass, and induced a specific cytotoxic T-lymphocyte (CTL) response against 
the tumor cells [120]. Either activation of DCs by IFNα, or apoptosis induced in tumor cells 
by IFNα may have resulted in improved antigen uptake by DCs and induced a potent CTL 
immune response against the tumor [120]. IFNβ has also been successfully used as a gene 
therapy approach for treating brain tumors in pre-clinical models and also in clinical trials. In 
a mouse model of brain tumors using GL261 cells, it was found that intratumoral delivery of 
IFNβ gene in liposomes significantly reduced the tumor volume. Furthermore, the authors 
demonstrated that this effect was dependent on CD8+ but not CD4+ T-cells [121]. IFNβ loaded 
liposomes have been delivered directly into the surgical cavity of 5 patients with recurrent 
malignant glioma after tumor resection. Of these, 2 patients survived for more than 2 years 
before succumbing to the disease [122]. Another approach that is currently being tested in a 
Phase I dose escalation clinical trial is the use of adenoviral vectors to deliver IFNβ directly 
into the surgical cavity following resection of glioma [123]. 
Type II Interferons 
Interferon γ (IFNγ) is the only interferon known to bind to the type II IFN receptor. Intracranial 
delivery of IFNα using gene therapy reduced tumor growth in pre-clinical models of glioma 
by activation of the immune system [124] and inhibition of angiogenesis [125]. Delivery of 
IFNα and TNFα in combination into established mouse glioma using recombinant adenoviral 
vectors led to a significant increase in survival [126]. However, these results were not as striking 
as those obtained for IFNα and IFNβ, suggesting that IFNγ may not be the most efficacious 
choice for translation into clinical trials. 
IL-2 
GENE THERAPY OF BRAIN TUMORS USING INTERLEUKINS 
Interleukins (IL) are a family of small cytokines produced by leukocytes that play a key role 
in coordinating the response of other immune cells during an immune response. Many 
interleukins are important for proliferation or activation of immune cell subtypes, including 
IL-2, IL-3 and IL-4. However, as we described above, some interleukins such as IL-10 actually 
inhibit immune responses. The efficacy of Interleukin-2 (IL-2), IL-4, and IL-12 have been most 
thoroughly studied in pre-clinical brain tumor models and will be discussed here. 
IL-2 is an interleukin produced primarily by T-cells. It promotes the proliferation of a variety 
of T-cells in vitro, including TH and cytotoxic (TC) T-cells [127-129]. In vitro studies have 
demonstrated that IL-2 is required for T-cell proliferation, activation and effector responses. 
Consequently, it has been extensively studied as a potential therapeutic agent for treating 
glioma. It was reasoned that by increasing T-cell proliferation and activation at the site of the 
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tumor, the anti-tumor immune response could be increased. When syngeneic 9L tumor cells 
engineered to express IL-2 were introduced into the CNS of rats, it was found that tumors 
developed in the CNS. These grew more slowly than wild-type tumors, but all of the animals 
eventually succumbed to the disease irrespective of IL-2 expression [130]. It was later found 
by the same group that IL-2 producing cells transplanted into the CNS could effectively 
eliminate established tumors by inducing immunity in peripheral tissues. This was 
accompanied by an increase in cytolytic T-cell activity against 9L cells when analyzed by 
Chromium release assay [131]. Combined administration of IL-2 with IFNγ, or IL-2 with IL-12 
and P53 were also found to delay tumor growth in rodent models of glioma [132,133]. 
Unfortunately, none of these combined therapies were very effective at eliminating tumor cells. 
With the recent development of IL-2 deficient mice and IL-2 receptor deficient mice, it has 
become apparent that T-cell proliferation is redundant in vivo and IL-2 deficiency does not 
decrease the numbers of T-cells at the site of infection. Instead of indiscriminately inducing 
T-cell proliferation, it is now believed that the principle function of IL-2 is to stimulate the 
proliferation of regulatory T-cells (TReg). CD4+/CD25+ TReg cells are absent in mice lacking 
either IL-2 or IL-2 receptor, and autoimmune disorders invariably develop in these mice, 
underscoring the importance of IL-2 in maintaining T-cell tolerance [134-136]. Consequently, 
IL-2 may not be a useful transgene for inducing robust immune responses against brain tumors. 
IL-4 
IL-12 
IL-4 is commonly associated with the induction of a type II TH response. TH2 responses are 
most important when defending against larger pathogens such as parasites, and also plays an 
important role in allergy [137]. IL-4 is produced by T-cells and regulates the maturation and 
proliferation of B-cells, mast cells and T-cells [138-142]. IL-4 expressing neuronal progenitor 
cells were injected into established tumors in both rats and mice. This was found to increase 
the survival of glioma bearing animals compared with controls [143]. In a related publication, 
9L tumor cells were transfected with IL-4, IL-12, GM-CSF or IFNα. Although subcutaneous 
injection of 9L cells expressing IL-4, GM-CSF and IFNα was found to promote immunity to 
intracranial administration of parental 9L cells and prevented the establishment of intracranial 
tumors, only IL-4 was found to improve survival in animals with pre-existing tumors. One 
drawback of this approach was that rat 9L cells were transfected with mouse cytokines [144], 
which may have resulted in the incorrect assessment on the efficacy of GM-CSF, IL-12 and 
INFα when compared with IL-4. In fact, an earlier study by Sampson et al., found that GM- 
CSF and not IL-4 was effective in eliminating tumors in a mouse model of glioma [145]. 
Notwithstanding, a pilot study designed to study the efficacy of tumor cells expressing IL-4 
and HSV-TK in combination to bolster the anti-glioma immune response has been undertaken 
in patients with malignant glioma [146]. 
IL-12 is a cytokine that is associated with polarizing T-cells towards a type I TH response 
(TH1) by mediating the differentiation of naïve T-cells. Systemic administration of 
recombinant IL-12 has been demonstrated to improve survival in a variety of rodent tumor 
models [147,148]. C57BL/6 mice bearing intracranial GL26 gliomas were treated by 
intratumoral injection of adenovirus expressing IL-12 (AdmIL-12), or control virus. IL-12 was 
found to significantly improve survival in these animals, indicating that IL-12 was able to delay 
tumor growth. Although enhanced infiltration of CD8+ and CD4+ T-cells was detected in the 
tumor tissue of animals injected with AdmIL-12, no significant increase in target cell lysis was 
noted compared animals treated with control virus [149]. This data suggests that while IL-12 
is capable of inducing increased T-cell proliferation and infiltration into the tumor, antigen 
presentation is not markedly increased and the majority of these T-cells are as inefficient at 
tumor lysis as in control animals. To circumvent this problem, Yamanaka et al., designed a 
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DC that constitutively produces Semliki Forest Virus carrying the IL-12 transgene (SFV IL-12) 
[150]. C57BL/6 mice bearing B16 tumors in the CNS were treated after 7 days with dendritic 
cells producing either SFV-IL-12 or control viruses. It was found that immunization with 
dendritic cells pulsed with SFV-IL-12 resulted in long-term survival in 40% of animals. This 
was associated with an increase in IFNγ production by murine splenocytes [150]. 
DENDRITIC CELLS 
A limitation with using either interferons or interleukins is that although they stimulate various 
effector immune cells, they do not improve antigen presentation to DCs. Thus, although there 
is an increase in tumor infiltrating T-cells at the tumor, there is no increase in the percentage 
of T-cells that are stimulated by tumor antigens. To address this problem both co-injection of 
DCs and gene therapy utilizing co-stimulatory molecules or DC growth factors have been 
attempted. 
Presentation of tumor antigen to T-cells and subsequent activation of the antigen-specific T- 
cell can occur directly, via MHC expression on the surface of the tumor cells to activated 
antigen specific T cells during the effector phase of the immune response, or indirectly, utilizing 
specialized APCs called DCs, during the activation of naïve T lymphocytes within the lymph 
nodes. Direct presentation of antigen is required for cytotoxic T-cell mediated killing of tumor 
cells and occurs when activated tumor-antigen specific CD8+ T-cells bind via the T-cell 
receptor (TCR) to MHC class I molecules, present on the surface of tumor cells, that display 
tumor antigen. Co-stimulatory molecules such as B7.1 (CD80) are expressed on the cell surface 
of DCs and other APCs and are required to first activate naïve T-cells following binding of the 
TCR with MHC molecules displaying the tumor antigen. In fact, antigen presentation to naïve 
T-cells in the absence of co-stimulatory molecules leads to T-cell tolerance rather than effector 
T-cell function. Usually, specialized APCs such as DCs are first required to present antigen to 
naïve, antigen specific T-cells in order to activate these T-cells. However, the possibility of 
using a gene therapy approach to express co-stimulatory molecules on MHC-expressing tumor 
cells and activate tumor specific T-cells. This was thought would circumvent the necessity of 
dendritic cells to first activate naïve T-cells. In a mouse model of glioma, it was found that 
B7.1 expression on tumor cells within the CNS was sufficient to improve survival in 60% 
animals for longer than 120 days [151]. Survival was significantly greater than animals injected 
with wild-type tumor cells, which survived for less than 20 days. However, the tumor model 
used in this study was injected into the subarachnoid space, a region of the brain with a large 
number of infiltrating immune cells, including T-cells and dendritic cells [151]. In two separate 
studies, one using transfected glioma cells and the other using adenovirus expressing the B7.1 
transgene to infect glioma cells in vitro before intracranial implantation, a very weak anti-tumor 
response was observed This suggests that B7.1 expression alone is not sufficient to induce 
strong anti-tumor immunity against brain tumors [152,153], most likely because priming of 
naïve T lymphocytes normally occurs within the microenvironment of the lymph nodes. 
Other groups have used purified dendritic cells alone, or in combination with other therapies, 
to increase the levels of APCs at the site of the tumor. In effect, this approach is designed to 
develop a dendritic cell vaccine against the tumor by stimulating various components of the 
immune system. This has proved to be a successful approach in pre-clinical trials and there are 
currently at least 20 Phase II and one Phase III clinical trials ongoing in the US that involve 
injection of dendritic cells either directly into the tumor, or in the periphery [154-159]. 
Our group has developed a novel approach for increasing DC infiltration into the tumor. First 
generation, replication-defective adenoviral vectors (RAd) were used to deliver human soluble 
Fems-like tyrosine 3 ligand (Flt3L) directly into the tumor. Flt3L is a potent inducer of dendritic 
cell differentiation, proliferation, and activation [160-162]. Considering that administration of 
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purified recombinant Flt3L induces infiltration of dendritic cells into tumors and tumor 
regression [163], our hypothesis was that expression of high levels of this transgene within the 
brain tumor using RAd vectors would increase intratumoral DCs infiltration and enhance the 
immune response against the tumor. Intracranial injection of RAdFlt3L significantly improved 
survival in a rat model of glioma. A large increase in macrophages and CD8+ T-cells infiltrating 
into the tumor was observed when compared with animals treated with controls [164]. This 
suggests that overexpression of Flt3L in the tumor stimulates an anti-tumor immune response 
that can eliminate tumor from the CNS. 
HSV1-Thymidine Kinase (TK) has become the most popular and widely tested approach using 
gene therapy for killing glioma cells in pre-clinical models [165-167]. TK converts a non-toxic 
compound called ganciclovir into a toxic product that interferes with DNA synthesis and 
induces cell death in glioma cells [165]. Patients with GBM were analyzed in a randomized 
clinical trial that either received standard therapy including surgical resection and radiation 
therapy or intracranial administration of TK in a retroviral vector in addition to standard 
therapy. Although there was no difference in the levels of peripheral blood mononuclear cells 
in either group, the authors demonstrated that patients that received TK in addition to regular 
therapy had elevated IFNγ producing cells when stimulated with autologous tumor cells. 
Furthermore, serum concentrations of IL-12 and soluble Fas ligand were also elevated in these 
patients when measured by ELISA [168]. This was evidence that TK improved the ability of 
the immune system to recognize the tumor, albeit weakly. A growing body of evidence shows 
that tumoricidal therapies could induce some degree of tumor immunity [168]. Apoptotic tumor 
cells are phagocytosed and processed efficiently by dendritic cells and mediate much stronger 
anti-tumor immune responses. We hypothesized that TK expression in the CNS, in combination 
with immune stimulation using Flt3L, would greatly enhance the immune response against the 
tumor by providing apoptotic tumor cells to a large population of activated dendritic cells. This 
recapitulates the strategies used by researchers to pulse DCs in vitro with tumor antigen, i.e. 
coincubation of DCs with apoptotic glioma cells is known to dramatically improve antigen 
presentation by facilitating the uptake and processing of tumor cells by DCs. 
To test whether Flt3L, or adenoviral vectors expressing other cytokines, could improve survival 
when combined with the cytotoxic RAdTK vector, viral vectors were injected into a large tumor 
model in rats. Animals injected with RAdFlt3L alone were all dead by day 20, while RAdTK 
treatment alone only improved survival in 20% of animals. However, when animals were 
treated with RAdFlt3L and RAdTK together, 70% survived for more than 175 days (Fig. 2). 
The use of first generation adenoviruses expressing IL-12, which promotes a TH1 immune 
response, CD40L, a co-stimulatory molecule had no effect on survival even when combined 
with RAdTK, suggesting that these immunostimulatory molecules were unable to promote a 
strong immune response against the tumor [169]. Thus, increasing dendritic cells within the 
tumor was a better approach to stimulating an immune response against the tumor than either 
increasing T-cell function, or increasing the expression of co-stimulatory molecules on tumor 
cells. Depletion of immune cells from glioma bearing animals before administration of 
RAdFlt3L and RadTK showed that CD4+ T-cells and macrophages were required for tumor 
regression [169]. In contrast, depletion of either CD8+ T-cells or NK cells did not affect the 
survival of animals treated with RAdFlt3L and RAdTK, suggesting that these cells did not play 
an important role in tumor regression [169]. 
A major advantage of stimulating DCs with tumor antigen in vivo instead of ex vivo is that DCs 
encounter the tumor antigen in their natural environment. Other co-factors involved in antigen 
processing and presentation are already available, simplifying the manipulation required to 
maximize anti-tumor immune responses. In addition, these gene therapies can be administered 
to patients at the same time as tumor resection by surgery, while ex vivo manipulation of DCs 
requires a week or more before the patient can receive the immunotherapy. This means that 
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the tumor is rapidly hit with the anti-tumor immune response, is not given any chance to recover 
from surgical resection and the therapy can take advantage of any inflammation naturally 
associated with the tumor resection. 
CHEMOTHERAPY AND IMMUNOTHERAPY 
Many immunotherapy trials are conducted in patients that have received or are currently 
receiving chemotherapy. The majority of contemporary chemotherapeutic agents are often 
designed to preferentially induce toxic chemical insults on tumor cells, leading to cell death 
by apoptosis, necrosis, or autophagy. Molecular targets are identified that make tumor cells 
more susceptible to chemical agents, for example, many target the rapid proliferation of tumor 
cells compared with normal somatic cells of the body. It was quickly realized that the immune 
response against the tumor is augmented in patients receiving chemotherapy at the same time. 
Low levels of cell death, when detected by immune cells, leads to the suppression of 
inflammation by stimulating the production of IL-10, TGF-β and prostanoids [170]. Apoptosis 
occurs frequently even in healthy tissues and this anti-inflammatory response is believed to 
prevent unnecessary inflammation and tissue damage in otherwise healthy tissues. Massive 
levels of cell death leads also to the release of heat shock proteins (HSPs) and uric acid, both 
known to be powerful inflammatory signals [171,172]. Studies using pre-clinical models have 
indicated that immunotherapy and chemotherapy can be synergistic in the treatment of brain 
tumors. For example, intracranial delivery of IL-2 alone marginally improves survival in an 
intracranial model of metastatic melanoma in the brain of mice. However, combined therapy 
with systemic administration of the chemotherapeutic drugs carmustine or carboplatin and 
IL-2-transduced tumor cells dramatically enhanced long-term survival with 70% of animals 
surviving for 70 days in a model where all controls were dead by day 20 [173]. It is important 
to note that radiotherapy and many chemotherapeutic agents currently used against GBM are 
also toxic to cells of the immune system. In particular, they tend to be toxic to rapidly dividing 
cells and this may serve to disrupt or delay the development of immunity against the tumor 
when combined with immunotherapy. A pre-clinical study noted that administration of 
dexamethasone, a glucocorticosteroid given to reduce pressure within the CNS casued by 
chemotherapy, in combination with IL-4 gene therapy completely abrogated the positive 
effects of IL-4 immunotherapy on the tumor bearing animals [174]. The dexamethasone dose 
found to cause complete immune suppression (250 μg/Kg/day) is equivalent to the dose given 
to human patients together with chemotherapy (4mg qid). Even doses 5 times lower than this 
still significantly inhibited the therapeutic benefits of IL-4 [174]. As a consequence, in clinical 
trials that use immunotherapy in combination with conventional treatment modalities, the 
immunotherapy is given first, and chemotherapy is given later after immunity against the tumor 
is allowed to develop. In this scenario, chemotherapy given later tends to augment the immune 
response that develops. For example, in a retrospective study of glioblastoma patients that 
received DC vaccination and conventional chemotherapy after surgery, it was reported that 
chemotherapy can improve the anti-tumor immune response in patients receiving 
immunotherapy. Vaccinated patients with glioblastoma that received subsequent 
chemotherapy were found to be tumor free for significantly longer than patients that received 
either vaccination alone, or chemotherapy alone and had elevated anti-tumor responses and 
CD8+ T-cell receptor excision circle content was predictive of response to chemotherapy 
[175]. These studies in preclinical animal models and clinical trials suggest that by enhancing 
the host immune response and reducing tumor burden, a synergistic effect leads to a more 
efficacious therapy. A very attractive approach to specifically reduce tumor burden and release 
tumor antigens which could be harnessed to stimulate a specific immune response against the 
tumor, is the use of targeted toxins. Although targeted toxins are already in clinical trials for 
treating GBM [176,177], below we will review the potential of combining targeted toxins and 
gene therapy to develop safer and long lived therapies for GBM. 
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TARGETED TOXINS FOR GLIOMA THERAPY 
Novel chemotherapeutic agents that can induce widespread tumor cytotoxicity without adverse 
toxicity to components of the immune system or healthy surrounding tissue are highly 
desirable, as these would improve the efficacy of immunotherapies currently being developed 
[178]. Receptors for the urokinase-type plasminogen activator (uPA) [179], transferrin 
[180-182], pleiotropic immunoregulatory cytokines [183-188] and growth factors [189,190] 
are overexpressed by human brain tumors but are virtually absent in the normal brain. Such 
specificity makes these receptors very attractive targets for targeted therapeutic approaches in 
glioma, minimizing any putative adverse side effects to normal brain tissue. Thus, ligands of 
these receptors, such as IL-13, uPA, EGF and transforming growth factor α (TGF-α) have been 
fused to the catalytic and translocation domains of highly cytotoxic bacterial products, 
including Pseudomona [185,190,191] and Diphteria toxins [179,187,189,192], in order to 
selectively kill glioma cells (Fig. 3). 
IL-13 
IL-4 
Established glioma cell lines, primary glioblastoma cell cultures and surgical glioma biopsies, 
express a variant of the IL-13 receptor, IL13Rα2, different from its physiological counterpart, 
i.e., IL13/IL4R [183-185,192,193]. The chimeric toxin composed of IL-13 and truncated 
Pseudomonas exotoxin, also termed IL-13 toxin, exerts a potent cytotoxic effect in most human 
glioblastoma cells tested in culture [185,187,191] and in vivo, in human xenografts consisting 
of glioma cells implanted in the flank of nude mice [194]. Moreover, the intratumoral 
administration of IL13-PE toxin into intracranial human glioma xenografts in immunodeficient 
mice showed highly cytotoxic effects without undesirable side effects [195]. To optimize the 
targeting of GMB-associated IL-13α2 receptor, a mutated human IL-13 which exhibits 50 fold 
higher affinity for the IL-13α2 receptor present in human glioma cells when compared to the 
wild-type IL-13 was engineered [196,197]. Fusion of this muIL-13 to PE resulted in an even 
more active cytotoxin on glioma tumors both in vitro and in vivo [196]. Importantly, the muIL13 
no longer interacts with the principal chain of IL4R, thus becoming ineffective in its binding 
to this receptor and signaling through the physiological IL13/IL4R of normal cells. This in turn 
decreases the already low toxicity of the chimeric toxin to normal cells [196]. Thus, although 
this mutant has negligible affinity by IL-13 receptor of normal cells, it exerts an enhanced 
cytotoxic effect towards glioma cells. The fact that IL13Rα2 is over-expressed not only in 
glioma cells, but also in other malignancies, including renal cell carcinoma [198], ovarian 
carcinoma [199], colon adenocarcinoma [185], epidermoid carcinoma [191], AIDS-associated 
Kaposi‟s sarcoma [200], prostate carcinoma [201] and pancreatic cancer [202], makes 
IL13Rα2 a unique target for anti-cancer therapy. In a PhaseI/II clinical trial, patients with 
glioblastoma multiforme were intratumorally injected with IL-13 toxin 8 days before surgical 
resection [176]. Necrotic areas were found in the tumors from half the patients, suggesting that 
the toxin successfully induced tumoral cell death. 
Human malignant glioma cell lines, primary cell cultures, and tumor specimens derived from 
surgical samples also express high affinity IL-4 receptors [186,188]. A circular permuted IL-4 
fused to a mutated form of Pseudomonas exotoxin, showed highly cytotoxic effect to cancer 
cells, but was not toxic to normal cells that express detectable IL-4 receptors, such as, B-cells, 
T-cells, and monocytes [203]. In vivo models of human glioblastoma in immunodeficient 
animals demonstrated that this immunotoxin also exhibits remarkable anti-tumor activity 
[204,205]. Phase I and Phase I/II clinical trial were developed for the treatment of recurrent 
glioblastoma multiforme, showing that IL-4 cytotoxin intratumoral administration to patients 
has an acceptable safety profile, being well tolerated at low doses [177]. These studies suggest 
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that this cytotoxin has anti-tumor activity, inducing necrosis in the tumor parenchyma, without 
histological evidence of toxicity to normal brain tissues [206]. Although local toxicity, such 
as intracranial edema, was reported, it seems to be due to tumor necrosis or occasionally to the 
volume of infusion. 
Transferrin 
The cytotoxic activity of targeted toxins constructed with human transferrin fused to 
Pseudomonas toxin or with Diphteria toxin was detected in human brain tumor cell lines 
[180,182]. In ex vivo experiments, pediatric brain tumor tissues were shown to be sensitive to 
transferrin-diphteria toxin [182], being that the toxin efficacy correlated with tumor grade. 
Transferrin receptor expression was high in the more aggressive and malignant tumors, such 
as glioblastoma multiforme and medulloblastoma, which were extremely sensitive to 
transferrin-diphteria toxin, while slow-growing and benign tumors expressed lower levels of 
receptor and were not as greatly affected by the toxin. Nude rats inoculated intracranially with 
human glioblastoma biopsy specimens, which develop highly infiltrative brain tumors, 
received direct interstitial infusion of transferrin-diphtheria toxin, showing strong anti-tumor 
efficacy [207]. In clinical trials, patients with recurrent malignant brain tumors, which were 
refractory to conventional therapy, were locally treated with the transferrin-diphteria toxin 
administered by high-flow interstitial microinfusion [208]. Although episodes of local toxicity 
in some of the patients were reported, direct interstitial infusion was shown to successfully 
distribute the toxin in the tumor and infiltrated brain areas, achieving anti-tumor responses 
without severe neurologic or systemic toxicity [209]. 
EGFR 
Overexpresssion of EGFR was found in more than 50% of high grade gliomas by several 
authors [187,210-212]. EGFR ligands, such as EGF and TGF, have been fused to Pseudomonas 
and Diphteria toxins. A chimeric toxin consisting of TGF and Pseudomonas toxin was 
systemically administered to nude mice bearing glioblastoma xenografts in the flank, inducing 
tumor regression [190]. However, mice bearing intracranial tumors required intratumoral 
administration of the toxin to increase survival time. Overexpresssion of EGFR was found in 
more than 50% of high grade gliomas by several authors [181,210-212]. EGFR ligands, such 
as EGF and TGF, have been fused to Pseudomonas and Diphteria toxins. Diphtheria toxin was 
fused to EGF and systemically administered to nude mice bearing subcutaneous human glioma. 
The toxicity of the fusion protein at high doses included loss of activity, reduced oral intake, 
and dehydration, elevated blood urea nitrogen, creatinine, aspartate transaminase, and alanine 
transaminase and renal tubular necrosis. However, tumor regression was seen in all animals, 
while relapses occurred 25% of the animals [189]. A chimeric toxin consisting of TGF and 
Pseudomonas toxin was systemically administered to nude mice bearing glioblastoma 
xenografts in the flank, inducing tumor regression [190]. However, mice bearing intracranial 
tumors required intratumoral administration of the toxin to increase survival time. In a Phase 
I trial the dose limiting toxicity of this chimeric toxin was determined after convection- 
enhanced delivery in patients with recurrent malignant brain tumors. In this study, which 
included 20 patients, the maximal tolerated dose could not be established, being the overall 
median survival 23 weeks after intracranial administration of the toxin [213]. Considering that 
EGFR is overexpressed not only in malignant brain tumors, but also in other neoplasias, 
including squamous cell carcinomas, adenocarcinomas, sarcomas, brain and germ line tumours 
[214], this receptor constitutes a promising target for anticancer therapy. 
Although the expression of one or more of these receptors is wide spread between malignant 
brain tumors, which of these is overexpressed in each particular patient needs to be determined 
prior the treatment for the therapy to be successful or the administration of a cocktail of chimeric 
toxins could address the individual sensitivity to this novel and promising therapy. A drawback 
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to the use of these toxins in clinical setting is that the half-life after intracranial administration 
is short requiring long periods of constant intracranial infusion. An approach that combines 
gene therapy with the targeted toxin technology may circumvent this problem by continually 
expressing chimeric toxins within the CNS. 
CONSIDERATIONS WHEN USING IMMUNOTHERAPY AND GENE THERAPY 
TO TREAT GBM 
Auto-Immune Disorders Induced Through Immunotherapy 
Immunotherapy used to treat melanoma has been associated with autoimmune response to 
melanocytes, resulting in autoimmune vitiligo [215,216]. A major consideration with using 
immunotherapy to treat brain tumors, or any other brain disease, is that the CNS contains a 
number of antigens not normally visible to the immune system. Tolerance of the immune 
system to these antigens does not develop and later exposure of the immune system to these 
antigens may potentially induce a harmful autoimmune response. Recent research has 
illuminated many of the mechanisms leading to autoimmune disorders against CNS antigen, 
and in particular, in models of multiple sclerosis. It has been postulated that APCs may be able 
to take up CNS antigen process it and present it to naïve, antigen specific T-cells without the 
need to migrate to proximal lymph nodes. Furthermore, persistent presentation of dominant 
proteolipid protein (PLP) antigen is necessary to stimulate auto-immune diseases [217,218]. 
We have analyzed the motor coordination and immune cell infiltrates into the CNS of long- 
term survivors of glioma treated with RAdTK and RAdFlt3L. Lewis rats were used, as these 
have previously been shown to be susceptible to experimental autoimmune encephalomyelitis 
(EAE) [219,220]. None of the animals were observed to display any overt symptoms of EAE. 
However, elevated CD8+ T-cells infiltrating in the corticospinal tract and meninges of all 
survivors treated with RAdFlt3L, RAdIL-12 and RAdCD40L, suggests that this may be a side 
effect of immunotherapy against CNS tumors [169] although none of the long term surviving 
animals developed clinical auto-immune disease. 
IMAGING GENE THERAPY AND DISEASE PROGRESSION IN VIVO 
Accurate Assessment of Tumor Regression and Gene Therapy Distribution 
By inducing anti-tumor immunity, it is important to note that tumor regression will occur more 
slowly than with conventional chemotherapeutic agents. This is due to the nature of an immune 
response, which, after identifying antigen for destruction, undergoes a phase of clonal 
expansion where effector cells are produced in large numbers. This process can take a week 
or more, before these cells mature and enter the tumor, where they target tumor cells and induce 
cell death. In order to correctly monitor the response of the patient to the tumor, imaging 
systems currently available in the clinic and novel imaging technologies will be required. A 
number of imaging techniques are available and are applied in the field of neuro-oncology, 
including MRI scans, PET scans, PEBBLEs, 3T1HMR Spectroscopy and Infrared (IR) Imaging 
Spectroscopy [221]. Several useful applications exist for each imaging technique, especially 
for gliomas within the brain. MRI and PET scans provide an informed diagnosis of the tumor, 
determining the size, vascularity, severity and type (primary vs. metastic). They also track the 
progression of the tumor much more efficiently than biopsies, which can give an incorrect 
assessment of tumor size, due to the heterogeneous nature of gliomas. MRI and PET scans are 
non-invasive methods which can be used for checking the effectiveness of radiation treatment 
and gene therapy and provide a means to track the tumor pre- and post-operatively, denoting 
the area that needs to be excised (or that requires surgical treatment) and identifying remaining 
regions containing tumor infiltrates after resection. They also serve to monitor and assess the 
rate and extent of tumor regression following therapy, and in particular, will allow the physician 
to monitor any regions of the brain that may contain tumor infiltrates. 
Curtin et al. Page 14 
Magnetic Resonance Imaging (MRI) 
MRI uses a powerful magnetic field to determine the nuclear magnetic spin and resonance 
properties of a small volume of tissue. Different tissues have different nuclear magnetic spin 
and resonance properties, and by collating this information, a scan of the tissue or body can be 
produced. The use of MRI to detect tumors is based on the observation that tumors and normal 
tissue differ in the time required for nuclear magnetic relaxation [222]. Before surgery, imaging 
allows the surgeon to know if the glioma is embedded in an inaccessible area within the brain. 
If surgery is reasonable, imaging enables the opportunity to determine whether or not the tumor 
has been completely or partially removed. MRI diffusion imaging provides fibre-tract mapping, 
thus enabling the surgeon to plan the surgical strategy more efficiently. Once the tumor is 
removed, intraoperative MRIs can detect remaining tumor infiltrates within the brain. To aid 
surgical accuracy, 3D imaging techniques are being developed to reveal all of the 
heterogeneous aspects of GBM [223]. These systems will improve the oncologist‟s 
understanding and knowledge of the tumor; size, location, and infiltration into surrounding 
CNS tissue and allowing more successful tumor resection. 
Many imaging techniques are able to track the progression and grade of the tumor. Often 
imaging relates directly to the histopathological characteristics and the clinical behavior of the 
tumor. For example, a biopsy may indicate a low-grade tumor; however, while that particular 
section of the tumor expresses traits of a low-grade tumor, other portions of the tumor may 
express high-grade tumor characteristics such as invasion or metastasis. By comparing old 
MRIs to more recent ones, oncologists can establish a treatment appropriate for that specific 
tumor progression pattern. Successive imaging surveillance allows early detection of tumor 
progression, for progression is variable depending on age, etc. MRI‟s may also elucidate 
clinical behavior unexplainable by biopsy sections. By comparing changes in vascular volume 
to changes of tumor size after gene therapy treatment, one can be able to verify whether or not 
the treatment is effective. 
Positron Emission Tomography (PET) 
Usually, brain tumors are visualized with different, complimentary imaging techniques. While 
MRI detects changes in tissue density, and is useful for studying the anatomy surrounding the 
brain tumor, PET scanning is often a more sensitive technique for detecting small tumors. 
Unlike MRI, PET scanning detects the decay of a radioactive molecules. Chemical tracers such 
as amino acids labeled with radioactive atoms such as Carbon-11, Nitrogen-13 Oxygen-15, 
Fluorine-18, or Iodine-124 can be injected into patients with brain tumors. These can detect 
early lesions of the tumor using PET scans, whereas CT and MRI scans are often unable to 
identify the presence of small or narrow regions of tumor. Because certain amino acids 
accumulate intensely at an early stage of the tumor, the tumor mass can be readily distinguished 
from normal brain tissue using radiolabelled amino acid tracers [224,225]. This is of particular 
use when trying to identify tumor metastases, or in the case of glioma to detect regions of the 
brain with small numbers of infiltrating tumor cells. 
The resolution of PET is currently less than 1 mm, sufficient to allow researchers that use 
rodent models of brain tumors to utilize micro-PET imaging. This allows researchers to 
accurately monitor the growth kinetics of the tumor in response to numerous therapies. 
Numerous tracking methods exist, each one depending on the expression of the reporter gene. 
A truncated form of the dopamine receptor (DR2R80A) and TK can both be used as reporter 
genes in tumor cells implanted into rodents and have been tracked by PET scan imaging 
[226-229]. Modified, radiolabelled dopamine analogues and TK substrates can be injected 
systemically into the animal where they diffuse across the blood brain barrier and subsequently 
accumulate in the CNS in regions with elevated expression of the reporter genes DR2R80A or 
TK (Fig. 4A). TK is a viral protein, and is not normally expressed in the CNS. Consequently, 
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TK allows the identification of this reporter gene expression to a very high degree of sensitivity. 
By expressing the reporter gene in glioma cells, researchers have monitored the progression 
of the tumor, as well as size and growth after therapy and/or resection. Therapeutic efficacy of 
the treatments to be tested is determined based on levels of reporter gene expression in live 
rodents, thus eliminating the need to euthanize the subjects. This reduces the number of animals 
required for each study and improves the ability of researchers to assess the efficacy of their 
therapy [224]. In contrast, Dopamine receptors are present in the CNS. However, DR2R80A 
can be used to image in the brain striatum as this region is completely devoid of Dopamine 
receptors. A major advantage with PET over other imaging systems is that several markers can 
be used simultaneously, thus enabling the researcher multiple tracing options. 
Bioluminescence Imaging 
PET detects gamma rays, emitted following the radioactive decay of short-lived isotopes to 
build a 3 dimensional image within the CNS. In pre-clinical rodent models, light rays emitted 
following the conversion of substrate into product can also be detected through layers of tissue 
using a bioluminescence imaging system with a cooled charge couple device (CCD) camera 
(Fig. 4b). Firefly and Renilla luciferase catalyzes the emission of light during the conversion 
of substrate into product. It has been shown that D-luciferin is an exclusive substrate for firefly 
luciferase, while coelenterazine is only metabolized by renilla luciferase in vitro and in vivo, 
and this has opened up the possibility of imaging two separate targets in vivo, one with Firefly 
luciferase and the other with Renilla luciferase [230,231]. Unlike PET, bioluminescence 
imaging does not give high resolution, 3 dimensional images of the tumor. However, the size 
of the tumor is proportional to the amount of light emitted, and this can be used to estimate the 
tumor volume. Furthermore, equipment for bioluminescent imaging is more affordable than 
microPET and safer as it does not involve the use of radiolabelled dyes. 
Expression of Luciferase has been used by researchers to monitor the growth kinetics of 
intracranial tumors, and to track the migration of neural precursor cells (NPCs) in vivo. Tumor 
cells were generated that express Renilla luciferase and these were implanted into nude mice. 
Immortalized NPCs were generated that express Firefly luciferase and the therapeutic 
transgene soluble TRAIL (sTRAIL). Migration of these NPCs into brain regions containing 
tumors was tracked using the Firefly luciferase substrate D-Luciferin. Tumor volume was 
estimated based on total light produced when mice were injected with the Renilla luciferase 
substrate ceolenterazine. Mice that received NPCs expressing sTRAIL displayed significantly 
slower growth kinetics compared with control NPC injected animals [108]. Luciferase 
substrates can also be engineered to require an activation step by a cellular enzyme before 
being catalyzed by luciferase enzyme. For example, D-Luciferin has been conjugated with 
DEVD and is only converted to product with the liberation of light after it has been processed 
by active Caspase 3, a hallmark of apoptotic cells. This has allowed researchers to monitor the 
activation of Caspase 3, and consequently the extent of apoptosis, in vivo in a mouse model of 
glioma following treatment with sTRAIL [109]. 
Future Directions of Imaging in Gene Therapy 
An exciting future direction for imaging with PET scanning and bioluminescence imaging is 
in the field of gene therapy. Assays exist for the majority of chemotherapeutic agents, to 
determine the pharmacokinetic and pharmacodynamic properties of the compounds in the 
patient. This is often found to vary substantially and the dose of a substance must be increased 
or decreased accordingly to obtain maximum therapeutic benefit. No reliable, relatively non- 
invasive method has yet been developed that can accurately assess the distribution and 
expression of therapeutic transgenes within the brain following injection of viral vectors. This 
is a major drawback in gene therapy and severely limits the ability to modify the dose if 
required. It is hoped that incorporation of genes into these viral vectors that can be detected 
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using PET or bioluminescence imaging techniques will allow for a more detailed assessment 
of transgene expression and distribution in the patient. Different reporter genes can be 
incorporated into the same vector. In one application, a lentivirus was constructed to express 
both TK and firefly luciferase. When cells stably infected with lentivirus were injected into 
mice, both luciferase and TK could be imaged using Bioluminescent imaging and microPET, 
respectively [232]. Likewise, three reporter genes were detected independently in live mice 
bearing 293T cells transfected with TK, Renilla luciferase and monomeric red fluorescence 
protein (mRFP1). Excitation of mRFP1 occurs at wavelengths of 500nm and 584nm while the 
maximum emission occurs around 607nm (Fig. 4c). The activity of each reporter gene was 
shown to be preserved, suggesting that multiple reporter genes can be used in combination 
both in a clinical setting and also for pre-clinical research [233]. A second useful application 
will be to monitor the infiltration of specific immune cells into the tumor following 
immunotherapy, allowing more accurate quantification of the extent of the immune response 
against the tumor. 
CONCLUSIONS AND FUTURE PROSPECTS 
Novel treatments for brain cancer (GBM) require the development of approaches which 
encompass several mechanisms of action, including different modes of cell death and immune 
stimulation. These novel therapies would work synergistically with the best treatment options 
currently available; i.e., surgery, radiotherapy and chemotherapy. Gene-based therapies are 
actively pursued to treat GBM, include oncolytic viruses to selectively replicate in cancer cells, 
causing their destruction; anti-angiogenic targets that aim at depriving the growing tumor of 
new blood vessels needed for it to spread; targeted toxins, which after delivery into tumor cells 
will cause their death; immune-stimulatory targets aimed at eliciting an anti-tumor immune 
response to inhibit tumor growth and prevent the spread of metastatic disease. Other exciting 
approaches are targeted at inhibiting signal transduction pathways, activated in GBM and 
shown to mediate tumor progression. 
Although many of these approaches have shown excellent efficacy with low or no toxicity in 
preclinical animal models, their success has not been reproduced in human clinical trials. There 
are several reasons for this, such as the need to enhance the specificity and efficacy of the gene 
transfer vectors and the therapies. This can be achieved by the use of targeted vectors, which 
have been engineered so that they can only infect tumor cells; or the use of the cancer cells‟ 
specific promoters which will drive the expression of therapeutic molecules exclusively in the 
tumor. The ability to generate a systemic long lived anti-tumor immune response is also a 
critical advancement which would prove very powerful for the treatment of GBM, which 
inevitably recurs. Immune stimulatory approaches mediated through the delivery of genes 
which induce immune cell recruitment and/or activation is an approach which is being actively 
pursued for the treatment of GBM. For the clinical implementation of these therapies, it is 
imperative to be able to monitor disease progression and persistence of the gene therapy in 
vivo, using non-invasive imaging techniques. This is an exciting technology which will enable 
the monitoring of the persistence of the therapeutic vectors and also their putative bio- 
distribution. 
Perhaps the biggest challenge before these gene-based therapies can be successfully and safely 
implemented to treat GBM in human patients, is the issue of the toxicity and bio-distribution 
of the gene transfer vectors used. Also, the pre-existing immune response to the vectors can 
have very serious deleterious effects, not only by decreasing the effects of the therapy by 
inhibiting therapeutic gene expression, but also by causing severe, systemic, immune-related 
side effects. Again, this is an area which is the focus of many investigations and has led to the 
development of better and safer vectors. 
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Fig. (1). 
Immune cell surveillance of the normal and tumor bearing brain. In the normal brain, only 
memory CD4+ T-cells are found within the brain parenchyma while other immune cell types 
are restricted to the cerebrospinal fluid and meningeal layers. Tumors affect the local and 
systemic immune environment to evade immune detection by producing cytokines like 
TGFβ, IL-10 and PGE. CD4+ T-cell numbers are reduced systemically. Meanwhile tumors are 
infiltrated with macrophages and CD8+ T-cells whose normal immunological functions are 
blocked in the tumor environment. 
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Fig. (2). 
Immunotherapy of brain tumors using RAdFlt3L and RAdTK. A. Survival curve from 
rats treated ten days after tumor implantation with replication deficient adenoviruses. RAdTK 
+Flt3L results in tumor regression in 80% of animals (modified from Cancer Research [169]). 
B. Brain section from a glioma survivor 240 days after tumor implantation followed by RAdTK 
and RAdFlt3L treatment. Brain sections were stained with vimentin to detect any reminant of 
tumor cells. C and D. Brain sections from animals treated with either saline or RAd TK+Flt3L 
10 days after tumor implantation. While 80% of animals treated with RAd TK+Flt3L survive, 
neuropathological analysis of those who secumb shows immune cell infiltration that is distinct 
from saline treated controls. As with human tumors, rat CNS-1 gliomas are heavily infiltrated 
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with macrophages (ED1 staining) regardless of treatment modality. B cells (CD45R staining), 
cytotoxic T cells (CD8 staining), and Natural Killer cells (CD161a staining) are all increased 
in treated animals compared to controls. 
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Fig. (3). 
Targeted toxins for the treatment of glioma. Human brain tumors have been shown to 
overexpress several receptors, including urokinase-type plasminogen activator receptor, 
transferring receptor, pleiotropic immunoregulatory cytokine receptors and growth factor 
receptors. The expression of these receptors seems to be more abundant in malignant tumors, 
than in benign, slow growing tumors. Since these receptors are virtually absent in the normal 
brain, they have been targeted in several therapeutic approaches in the treatment of glioma, to 
avoid toxicity to normal brain tissue. Ligands of these receptors, such as IL-13, IL-4, uPA, 
transferrin, EGF and TGF have been fused to the catalytic and translocation domains of highly 
cytotoxic bacterial products, including Pseudomonas and Diphteria toxins (T), in order to kill 
selectively malignant glioma cells, but preserving surrounding normal brain tissue. 
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Fig. (4). 
Stratagies for live animal imaging A. HSV1-Thymidine kinase (TK) is expressed by a first 
generation adenoviral vector (RAd) and catalyzes the phosphorylation of the prodrug 
ganciclovir (GCV) to generate GCV-monophosphate (GCV-P). Cellular kinases further 
phosphorylate to form a nucleotide analogue GCV-triphosphate (GCV-P-P-P) which interferes 
with DNA synthesis and induces apoptosis in dividing cells. In addition, the HSV1-TK protein 
interacts with the imaging substrate (124I)-labelled-2‟-fluoro-2′-deoxy-1-ß-D- 
arabinofuranosyl-5-iodouracil (I*-FIAU) to form a phosphorylated version of the molecule 
(I*-FIAU-P) which can be used for PET imaging. I*-FIAU is membrane permeable and can 
diffuse freely through the plasma membrane of cells. However, following phosphorylation by 
TK, I*-FIAU-P becomes hydrophylic and remains trapped in the cell expressing TK. 
Consequently, the concentration of radioactive 124I increases only in cells expressing TK and 
is rapidly cleared from the rest of the body. B. A RAd expressing Firefly Luciferase was injected 
into the striatum of a mouse. Seven days later the mouse was injected with the substrate D- 
Luciferin and the animal was imaged using a CCD-based in vivo imaging system (IVIS, 
Xenogen). The intensity of light production was evaluated and is represented using a color 
scale with red being regions with most intensity and blue being regions with lowest intensity, 
as indicated on the scale to the right of the image. C. A RAd expressing monomeric red 
fluorescent protein (mRFP) was infected onto a monolayer of 293 cells. The monolayer was 
imaged using a inverted fluorescent microscope 24 hours after infection (Axiovert 200, ZEISS). 
